Organisation paid for research Program year 2025 Source: CMS Open Payments

Clinvest Research

Neither a doctor nor a teaching hospital

Research payments

$334,721

148 payments

Through program year 2025, Clinvest Research is reported as receiving $334,721 in research payments, across 148 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $49,500 97
2024 Research $69,262 3
2023 Research $83,743 3
2022 Research $15,486 1
2021 Research $40,861 17
2020 Research $75,856 26
2019 Research $13 1

Breakdown

Who paid Research payments · program years 2019–2025
  1. E.R. Squibb & Sons, L.L.C. $188,721 4 payments
  2. AbbVie, Inc. $110,647 42 payments
  3. Boehringer Ingelheim International GmbH $21,064 96 payments
  4. H. Lundbeck A S $6,070 1 payment
  5. AstraZeneca Pharmaceuticals LP $4,750 1 payment
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $3,455 3 payments
  7. Amgen Inc. $13 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Phase III PsA (primary WK16 driving Submission) - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Psoriatic Arthritis who are Na ve to Biologic Disease-modify $79,317 1 payment
  2. Phase III PsA #2 (Wk52 driving submission) - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Psoriatic Arthritis who are Na ve to Biologic Disease-modifying A $54,933 1 payment
  3. A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Nave to Biologic Disease-modifying Anti-rheumatic Drugs $38,986 1 payment
  4. M15-925 $29,011 9 payments
  5. A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs) $28,688 9 payments
  6. Obesity Long term safety in patients with CV risk $18,755 4 payments
  7. Phase III PsA - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Psoriatic Arthritis who are Na ve to Biologic Disease-modifying Anti-rheumatic Drugs. $15,486 1 payment
  8. M16-560 $13,500 2 payments
  9. M15-572 $11,811 4 payments
  10. M15-554 $11,308 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record